Axsome Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AXSM and other ETFs, options, and stocks.

About AXSM

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. 

CEO
Herriott Tabuteau
CEOHerriott Tabuteau
Employees
925
Employees925
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2012
Founded2012
Employees
925
Employees925

AXSM Key Statistics

Market cap
13.04B
Market cap13.04B
Price-Earnings ratio
-64.45
Price-Earnings ratio-64.45
Dividend yield
Dividend yield
Average volume
706.33K
Average volume706.33K
High today
$242.89
High today$242.89
Low today
$237.78
Low today$237.78
Open price
$240.92
Open price$240.92
Volume
412.00K
Volume412.00K
52 Week high
$260.19
52 Week high$260.19
52 Week low
$96.09
52 Week low$96.09

Stock Snapshot

As of today, Axsome Therapeutics(AXSM) shares are valued at $241.00. The company's market cap stands at 13.04B, with a P/E ratio of -64.45.

During the trading session on 2026-07-25, Axsome Therapeutics(AXSM) shares reached a daily high of $242.89 and a low of $237.78. At a current price of $241.00, the stock is +1.4% higher than the low and still -0.8% under the high.

Trading activity shows a volume of 412K, compared to an average daily volume of 706.33K.

The stock's 52-week range extends from a low of $96.09 to a high of $260.19.

The stock's 52-week range extends from a low of $96.09 to a high of $260.19.

AXSM News

TipRanks 14h
Axsome’s CLARITY Trial Targets Sleepy Depression: What Investors Should Watch

Axsome Therapeutics Inc. (AXSM) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, mor...

Simply Wall St 2d
Axsome Therapeutics Wins FDA Acceptance For AXS 12 In Narcolepsy

Axsome Therapeutics reported that the FDA has accepted its New Drug Application for AXS-12 for the treatment of cataplexy in narcolepsy. The FDA does not plan...

Axsome Therapeutics Wins FDA Acceptance For AXS 12 In Narcolepsy
TipRanks 4d
Axsome Therapeutics Inc. Q3 2024 Earnings Report - Results, Call & Slides - TipRanks

...

Axsome Therapeutics Inc. Q3 2024 Earnings Report - Results, Call & Slides - TipRanks

Analyst ratings

90%

of 21 ratings
Buy
90.5%
Hold
9.5%
Sell
0%

People also own

Based on the portfolios of people who own AXSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.